Ke hoʻohālikelike ka poʻe i nā lāʻau lapaʻau o ka hanauna e hiki mai ana, hoʻokahi inoa e kū nui nei ʻo ka retatrutide. Ua ulu wikiwiki ka hoihoi i kēia mole no ka mea e hōʻike ana i kahi ala lāʻau lapaʻau ākea ma mua o tirzepatide, e ʻimi ana i ʻekolu mau mea hoʻokipa ma mua o ʻelua. I ka manawa like, ua loaʻa i ka tirzepatide kahi kūlana honua maoli ikaika: ua ʻae ʻia ʻo FDA, loaʻa i ke kālepa, a kākoʻo ʻia e nā hopena lapaʻau nui i ke ʻano 2 metabolism, obesity, a me ka obstructive sleep apnea i nā pākeke me ka momona. Hoʻokumu kēlā i kahi hoʻohālikelike koʻikoʻi. Ma kekahi ʻaoʻao, aia kahi agonist ʻelua i hoʻohana ʻia i kēia lā; ma ka ʻaoʻao ʻē aʻe he triple agonist hou aʻe i ʻike ʻia e ka poʻe nānā he hiki ke hana hou i ka lāʻau lapaʻau metabolic. Inā ʻo ka nīnau ʻo wai ka lāʻau i ʻoi aku ka hauʻoli mai kahi hiʻohiʻona hou, ʻoi aku ka manaʻo o ka retatrutide. Inā ʻo ka nīnau he aha ka lāʻau i ʻoi aku ka maʻalahi i kēia lā, alakaʻi maopopo ʻo tirzepatide. ʻO ke kī ʻo ka hoʻomaopopo ʻana i kahi o lākou i ʻokoʻa ai i ka mīkini, efficacy, kūlana hoʻoponopono, ʻike palekana, a me ka hiki ke lōʻihi.
ʻO Tirzepatid kahi peptide injectable i hoʻokahi pule i hoʻomohala ʻia e Lilly e hana nei ma ke ʻano he agonist ʻelua o ka GIP a me GLP-1 receptors. Ma ʻAmelika Hui Pū ʻIa, ua ʻae ʻia ʻo tirzepatide e like me Mounjaro no ka mana glycemic ma ke ʻano 2 metabolism a me Zepbound no ka hoʻokele kaumaha mau i nā pākeke me ka momona, a i ʻole ke kaumaha me ka liʻiliʻi o hoʻokahi maʻi pili kaumaha. Ua ʻae ʻia ʻo Zepbound i ka FDA no ka maʻi maʻi obstructive sleep apnea ma nā pākeke me ka momona. ʻO kēlā kūlana hoʻoponopono e hāʻawi iā tirzepatide i kahi pono kūpono i ka mākeke o kēia lā.
ʻO Retatrutid kekahi peptide injectable i hoʻokahi pule mai Lilly, akā hele i hoʻokahi ʻanuʻu i ka mechanistically. Ma kahi o ka hana ʻana ma luna o ʻelua mau mea loaʻa, he triple agonist e kuhikuhi ana i ka GIP, GLP-1, a me ka glucagon receptors. Ua wehewehe ʻo Lilly iā ia ma ke ʻano he molekele noiʻi, a mai Malaki-ʻApelila 2026 e noho mau ana ia i ka hoʻomohala ʻana ma mua o ka hoʻohana ʻana i ka lehulehu. Hōʻike maopopo ka ʻoihana ʻaʻole i ʻae ʻia ka retatrutide e kekahi ʻoihana hoʻoponopono a loaʻa i ke kānāwai wale nō i nā poʻe komo i nā hoʻokolohua lapaʻau kākoʻo ʻia e Lilly.
He mea koʻikoʻi kēlā kūlana hoʻokolokolo, akā ʻaʻole ia e hōʻemi i ke kumu e huki nui ai ka mole. Ke aʻo ʻia nei ʻo Retatrutid ʻaʻole wale i ka momona a me ke ʻano 2 metabolism, akā ma waena o kahi ʻāina cardiometabolic ākea, me ka maʻi cardiovascular i hoʻokumu ʻia, ka maʻi metabolic pili i ka ate, ka ʻeha haʻahaʻa haʻahaʻa i ka momona, a me ka ʻeha osteoarthritis e pili ana me ka momona a i ʻole ke kaumaha. Hōʻike kēia laula e ʻike ka poʻe noiʻi i ka retatrutide ʻaʻole wale ma ke ʻano he moho hoʻemi paona, akā ma ke ʻano he paepae metabolic ākea.
ʻO Tirzepatid ma ke ʻano he agonist ʻelua
Hoʻoulu ʻo Tirzepatid i nā mea loaʻa GIP a me GLP-1. Kākoʻo kēia hana ʻelua i ka hoʻomaikaʻi ʻana i ka huna ʻana o ka insulin, hoʻohaʻahaʻa i ka glucose koko, hoʻopaneʻe i ka hoʻokuʻu ʻana o ka ʻōpū, hoʻemi ʻia ka ʻai, a me ka hoʻēmi kaumaha. No nā maʻi he nui, ʻoi aku ka maikaʻi o kēlā hui ʻana. ʻO ia ke kumu i lilo ai ʻo tirzepatide i inoa nui i ka momona a me ka mālama metabolism.
Retatrutid ma ke ʻano he triple agonist
Hoʻoulu ʻo Retatrutid i ka GIP, GLP-1, a me ka glucagon receptors. ʻO ka ʻāpana glucagon ka mea e hoihoi nui ai. ʻOiai pili pinepine ʻia ka glucagon me ka hoʻonui ʻana i ka glucose i ke koko, ma ka pōʻaiapili lāʻau lapaʻau kūpono e kākoʻo pū paha ia i ka hoʻonui ʻana i ka ikehu a me ka metabolism momona. ʻO kēlā ala i hoʻohui ʻia ke kumu nui e kamaʻilio pinepine ʻia ai ka retatrutide he ʻoi aku ka ikaika ma mua o ka tirzepatide mai kahi hiʻohiʻona paona.
No ke aha e nānā pono ai nā poʻe loea i ka retatrutide
Mai ka ʻike ʻepekema, hōʻike ʻo retatrutide i kahi hoʻolālā metabolic ākea. ʻO Tirzepatid kahi hana nui i mua mai nā lāʻau lapaʻau ala hoʻokahi; ʻO retatrutide paha ka hoʻāʻo hou e hoʻonui i ka hopena therapeutic. ʻAʻole ia e hoʻolilo i ka 'ʻoi aku ka maikaʻi' i kēlā me kēia maʻi a i ʻole nā mea hoʻohana a pau, akā wehewehe ia i ke kumu i manaʻo pinepine ʻia ai ʻo ia ka moho hou. He ʻike kēia i hoʻokumu ʻia i ka ʻokoʻa ma waena o ka huli ʻana i nā mea hoʻokipa ʻelua a me triple a me nā hōʻailona hoʻemi kaumaha i ʻike ʻia i kēia manawa.
Ua hāʻawi mua ʻo Tirzepatid i ka hopena maikaʻi loa. I ka SURMOUNT-1, ua lilo nā mākua i Zepbound 15 mg i ka awelika o 20.9% o ke kaumaha o ke kino ma luna o 72 mau pule, a ma ke poʻo i ke poʻo SURMOUNT-5 haʻawina, ua hōʻike ʻo tirzepatide i ka 20.2% awelika kaumaha kaumaha ma 72 wiki me 13.7% me ka semaglutide. ʻO ia nā hopena nui ma kēlā me kēia kūlana.
ʻO ka Retatrutid naʻe, kahi e lilo ai ke kamaʻilio hoihoi. Ma Lilly's phase 2 obesity hopena i paʻi ʻia ma 2023, loaʻa ka retatrutide a hiki i ka 24.2% mean hoʻemi kaumaha ma 48 mau pule ma ke ʻano he hope lua. ʻO ka mea hou loa, ua hōʻike ʻo Lilly i ka Phase 3 type 2 metabolism data e hōʻike ana i ka hōʻemi ʻana o A1C o 1.7% a i 2.0% i nā wiki he 40 a me ka hoʻohaʻahaʻa kino-kaumaha a hiki i 16.8% ma ka 12 mg dose. Ua hōʻike pū ʻo Lilly i ka hopena o 2025 TRIUMPH-4 i ka obesity/overweight me ka osteoarthritis o ke kuli, kahi i hāʻawi ai ka retatrutide 12 mg i ka 28.7% hoʻemi kino-paona ma ka manaʻo efficacy, ʻoiai ʻokoʻa kēlā ʻano kikoʻī mai nā hoʻohālikelike ākea obesity-wale nō.
Māhele |
Tirzepatid |
Retatrutid |
Pili hua'ōlelo kumu |
Maikaʻi ma kēia ʻatikala |
Kiʻekiʻe, e like me ka mea e puka mai ana |
Nā pahu hopu |
GIP + GLP-1 |
GIP + GLP-1 + glucagon |
Kūlana o kēia manawa |
Ua ʻae ʻia ʻo FDA no ka metabolism type 2; 'Apono 'ia e like me Zepbound no ka obesity/overweight a me ka OSA i nā mākua me ka momona |
ʻImi ʻimi wale nō |
Loaʻa i kēia manawa |
Hoʻohana ʻia no nā hōʻailona i ʻāpono ʻia |
ʻO nā hoʻokolohua lapaʻau wale nō |
ʻO ka hoʻohaʻahaʻa kaumaha |
Paʻa a hoʻopaʻa ʻia i ke kālepa |
ʻOi aku ka ikaika o nā hōʻailona hiki i kēia manawa, akā naʻe ke kūkulu ʻia nei |
Hōʻike hou |
ʻO ka holomua nui ma mua o nā ala GLP-1 wale nō |
Manaʻo pinepine ʻia ʻo ia ka pae o ka hanauna e hiki mai ana |
Pilikia o ka overstatement |
Haahaa, no ka mea, ua aponoia |
ʻOi aku ka kiʻekiʻe, no ka mea ke puka mai nei nā hōʻike |
Manaʻo holoʻokoʻa |
ʻO ke koho kūpono maikaʻi loa i kēia lā |
ʻOi aku ka hoihoi o ka moho lōʻihi |
ʻO ka papaʻaina ka mea maʻalahi ke hoʻomaopopo: ʻo tirzepatide ka koho ʻoi aku ka ikaika o kēia mau lā, ʻoiai ʻo retatrutide ke koho ʻoi aku ka ikaika o ka wā e hiki mai ana.
No ka mea ua ʻae ʻia ka tirzepatide, ʻoi aku ka makua o kāna ʻōlelo palekana a ʻoi aku ka maopopo o ka lepili. Hōʻike ka ʻike huahana i nā hopena ʻino o ka ʻōpū e like me ka nausea, ka ʻōpū, ka luaʻi, ka paʻa ʻana, ka ʻeha ʻōpū, a me ka dyspepsia ma waena o nā pilikia maʻamau. Aia pū kekahi ʻōlelo aʻoaʻo a me nā ʻōlelo contraindication ma ka lepili ʻana o US.
Aia ʻo Retatrutid ma mua o kona ola ʻana, no laila ʻaʻole i piha kona kiʻi hoʻomanawanui. Ua hōʻike ʻia nā hopena metabolism Phase 3 a Lilly, ʻo nā hanana ʻino maʻamau ka maʻi ʻōpū, me ka nausea, ka ʻōpū, a me ka luaʻi ʻana, ma mua o ka piʻi ʻana o ka maʻi. Kūlike like ia me nā mea a nā kauka i ʻike ai ma waena o ka incretin-based therapies, akā pono mau ka retatrutide i ka manawa hou aʻe a me nā ʻikepili nui aʻe ma mua o ka hoʻomaopopo ʻana i kona ʻike piha.
Hiki i ka moleke ke nānā aku i ka ikaika a pono e akahele. ʻO ia ka helu kaulike ma ʻaneʻi. Hiki ke nānā aku ʻo Retatrutid i ka ʻoi aku ka maikaʻi ma ka mīkini a hiki ke hōʻoia i ka hopena no kekahi mau maʻi, akā ʻoi aku ka maikaʻi o ka tirzepatide i kēia manawa i kahi hoʻolālā palekana a me ka hoʻopaʻa inoa ʻana.
No nā poʻe maʻi a me nā kauka lapaʻau e hoʻoholo nei i kēia lā , ʻo tirzepatide ka pane kūpono no ka mea ua ʻae ʻia, kuhikuhi ʻia, a kākoʻo ʻia e ka lepili maʻamau. ʻO ia ke koho no ka hoʻohana honua maoli i kēia manawa.
No nā mea noiʻi, nā mea kiaʻi pipeline, a me ka poʻe heluhelu e makemake ana i kahi e hele ai ka metabolic therapy, ʻo ka retatrutide paha ka mea ʻoi aku ka hoihoi no nā kumu ʻekolu:
1. ʻO ka mīkini ākea ma o triple agonism.
2. ʻO nā hōʻailona hoʻemi paona ikaika loa i ka māhele 2 a me ka hoʻoikaika ʻana i nā mea hou o ka Phase 3.
3. ʻO kahi kapuaʻi hoʻomohala ākea ākea ma waena o nā kūlana pili i ka momona a me ka cardiometabolic.
No laila, ʻoiai ʻaʻole pololei ka ʻōlelo ʻana ʻo ka retatrutide ʻoi aku ka maikaʻi o ka mālama honua maoli, he mea kūpono ke ʻōlelo ʻana ʻo ka retatrutide ka moho a nā poʻe he nui e nānā pono nei no ka wā e hiki mai ana. Hoʻopaʻa kēlā framing i kāna ʻōlelo hoʻohiki a me kāna palena o kēia manawa.
Aia nā papa inoa hoʻokolokolo kūhelu no kahi haʻawina e hoʻohālikelike pololei ana i ka retatrutide a me ka tirzepatide i nā pākeke me ka momona, e hōʻike ana i ke ʻano o kēia hoʻohālikelike. Ke hoʻomau nei ka papahana retatrutide ākea a Lilly ma o nā haʻawina TRIUMPH a me TRANSCEND. ʻO ia hoʻi, ʻaʻole ka nīnau inā he mea nui ka retatrutide; ʻo ia inā ʻoi aku ka ikaika o kāna ʻikepili e hiki mai ana e hōʻoia i kahi hoʻololi therapeutic nui.
Inā hoʻomau nā hopena e hoʻomau i ka hoʻemi ʻana i ke kaumaha a me nā pōmaikaʻi metabolic ākea, hiki i ka retatrutide ke lilo i hoʻokahi o nā lāʻau lapaʻau momona o ka hanauna e hiki mai ana i ka hoʻomohala ʻana.
I ka hoʻohālikelike ʻana i ka tirzepatide a me ka retatrutide, ʻo ka hopena maikaʻi loa, ʻaʻole ia he 'lanakila,' akā ua noho lākou i nā kūlana like ʻole i ka ʻāina lapaʻau. ʻO Tirzepatid ka koho i hoʻopaʻa ʻia, kākoʻo ʻia e ka ʻae ʻia, loaʻa, a me ka hoʻohana lapaʻau nui. ʻO Retatrutid ka moho ʻoi aku ka nānā ʻana i mua, i kākoʻo ʻia e kahi mīkini triple-agonist ākea a me nā ʻikepili hoʻonui nui e hōʻike ana e hiki ke hoʻoikaika hou i ke kahua inā hoʻomau nā hopena e hiki mai ana. Mai ko mākou hiʻohiʻona, ʻo ia ke kumu e pono ai ke nānā nui ʻia ka retatrutide. Cocer Peptides Co., Ltd. no ka ʻike hou aku.
ʻAe. ʻO Tirzepatid ka FDA-apono ʻia no ke ʻano 2 metabolism e like me Mounjaro a no ka obesity/overweight a me OSA i nā pākeke me ka momona e like me Zepbound, ʻoiai e mau ana ka retatrutide i ka hoʻokolokolo.
No ka mea, ua hoʻoholo ʻo ia i ʻekolu mau loaʻa—GIP, GLP-1, a me ka glucagon—ma mua o ʻelua, hiki ke hoʻopuka i nā hopena metabolic ākea a me nā hopena hoʻemi kaumaha.
He ikaika loa nā hōʻailona mua a me ka waena, me ka hopena o ka momona o ka pae 2 a hiki i ka 24.2% mean o ka hoʻemi ʻana i ke kaumaha ma 48 mau pule a ma hope o ka hoʻāʻo ʻana me nā helu efficacy-estimend ʻoi aku ka nui ma kekahi mau heluna, akā pono mau ka makaʻala o ka hoʻohālikelike hoʻāʻo cross.
ʻAʻole. Ua ʻōlelo ʻo Lilly e loaʻa i ke kānāwai ka retatrutide ma o kāna mau hoʻokolohua lapaʻau wale nō, a ua ʻōlelo ka FDA i nā mea kūʻai mai ʻaʻole e kūʻai i nā huahana i ʻae ʻole ʻia i kūʻai ʻia ma ke ʻano he noiʻi-hoʻohana i nā lāʻau pili i ka GLP-1.
